The BioSciences Group of Fujitsu Announces New Technique for Increasing Efficiency in Transforming Difficult-to-Transfect Cells

Workflows Based on CELLINJECTOR(TM) Automated Microinjection Technology

Exhibit 49% Overall Efficiency of Transformation

May 02, 2006, 01:00 ET from BioSciences Group of Fujitsu Computer Systems

    WESTWOOD, Mass., May 2 /PRNewswire/ -- The BioSciences Group of Fujitsu
 Computer Systems today announced a new method that nearly doubles the
 efficiency of cell transformation in difficult-to-transfect cell types,
 based on the CELLINJECTOR(TM) automated microinjection technology.
     Dr. Michael J. McManus, vice president of Business Development for the
 BioSciences Group of Fujitsu Computer Systems, said, "We are pleased to
 announce a method leveraging the expertise of Fujitsu in nanotechnology and
 automation. The CELLINJECTOR vastly improves the efficiency and throughput
 of cell injections, easily performing thousands of successful injections
 per day compared to hundreds done manually." He added, "Researchers working
 on typically difficult-to-transfect cell types including embryonic stem
 cells and adult stem cells, among others, which have transfection
 efficiencies as low as 15-20% using standard reagents could benefit greatly
 from this technology. In a recent study using the CELLINJECTOR technique,
 overall efficiency of transformation of a mouse cell line was improved to
 approximately 49%, nearly double the reported averages for transfection for
 this cell type. This workflow requires less technical proficiency among
 users than existing manual microinjection systems, but provides throughputs
 of up to 10 times that of manual systems."
     One advantage of the CELLINJECTOR-based workflow is that other
 techniques such as electroporation can cause substantial cell damage.
 Another and perhaps even more problematic issue the new technique helps
 circumvent is the fact that in all bulk transfection approaches, it is
 impossible to differentiate between cells which successfully admitted the
 vector but failed to transcribe it from those cells which simply did not
 allow entry of the vector. As transformed cells are subsequently enriched
 for further study, it is difficult to ascertain whether the phenotype of
 the enriched, transfected population is the same as the general population
 of cells.
     Due to a combination of these limitations, the only viable solution has
 been manual microinjection of such cells -- a low-throughput, and
 prohibitively time- and labor-intensive method. Automated microinjection
 technologies such as CELLINJECTOR give researchers direct determination of
 which cells actually received construct, providing needed control over the
     CELLINJECTOR consists of an integrated, computer-controlled microscopic
 stage and microinjector system, a microfluidic handling system and pressure
 control machinery. The system enables automatic injection of suspended
 cells and operator-assisted automatic injection of adherent cells.
 CELLINJECTOR has a throughput several times higher than conventional
 microinjection, injecting up to 1,043 suspended cells in a single dish in
 30 minutes and 500-600 adherent cells in an hour -- whereas manual
 injection methods can usually only achieve hundreds of injections per day.
     For more information, please download the CELLINJECTOR whitepaper at
     About The BioSciences Group of Fujitsu Computer Systems
     The BioSciences Group of Fujitsu Computer Systems Corporation is an
 established leader in creating innovative and reliable solutions for
 experimental scientists. BioSciences Group solutions enable researchers to
 make in silico predictions about leads, targets, and interactions, and to
 validate these hypotheses experimentally. BioSciences Group offerings
 include the CELLINJECTOR system for high-throughput, automated cellular
 injection, and the CAChe(TM) suite of life sciences predictive modeling and
 automated docking tools, for drug discovery lead-generation. For more
 information, please see:
     About Fujitsu Computer Systems Corporation
     Headquartered in Sunnyvale, Calif., Fujitsu Computer Systems is a
 wholly owned subsidiary of Fujitsu Limited (TSE: 6702) committed to the
 design, development and delivery of advanced computer systems, application
 infrastructure software products, and managed services for the business
 enterprise. Through its TRIOLE strategy, the company offers a complete line
 of scalable and reliable servers, storage and middleware solutions, high-
 performance mobile and client computers, as well as professional services.
 Fujitsu Computer Systems has established itself as a strategic solutions
 provider to the world's leading organizations by offering technology
 innovation, customer choice, exceptional product quality and reliability,
 as well as outstanding customer service. More information on Fujitsu
 Computer Systems is available at
     About Fujitsu
     Fujitsu is a leading provider of customer-focused IT and communications
 solutions for the global marketplace. Pace-setting device technologies,
 highly reliable computing and communications products, and a worldwide
 corps of systems and services experts uniquely position Fujitsu to deliver
 comprehensive solutions that open up infinite possibilities for its
 customers' success. Headquartered in Tokyo, Fujitsu Limited (TSE: 6702)
 reported consolidated revenues of 4.7 trillion yen (US$44.5 billion) for
 the fiscal year ended March 31, 2005. For more information, please see:
     NOTE: Fujitsu, the Fujitsu logo, CAChe and CELLINJECTOR are trademarks
 or registered trademarks of Fujitsu Limited in the United States and other
 countries. All other trademarks and product names are the property of their
 respective owners.
     The statements provided herein are for informational purposes only and
 may be amended or altered by Fujitsu Computer Systems Corporation without
 notice or liability. Product description data represents Fujitsu design
 objectives and is provided for comparative purposes; actual results may
 vary based on a variety of factors. Specifications are subject to change
 without notice.

SOURCE BioSciences Group of Fujitsu Computer Systems